Alopurinol

alopurinol

Alopurinol je organsko jedinjenje, koje sadrži 5 atoma ugljenika i ima molekulsku masu od 136,112 Da.[1][2][3][4][5][6][7]

Alopurinol
Allopurinol V.1.svg
Allopurinol 3d structure.png
Klinički podaci
Prodajno ime7HP, Adenock, Ailural, Allo-Puren
Drugs.comMonografija
Način primeneOralno
Farmakokinetički podaci
Poluvreme eliminacije1-3 h
IzlučivanjeFekalno
Identifikatori
CAS broj315-30-0 ДаY
ATC kodM04AA01 (WHO)
PubChemCID 2094
DrugBankDB00437 ДаY
ChemSpider2010 ДаY
ChEBICHEBI:40279 ДаY
ChEMBLCHEMBL1467 ДаY
Hemijski podaci
FormulaC5H4N4O
Molarna masa136,112
  • O=C1N=CN=C2NNC=C12
  • InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10) ДаY
  • Key:OFCNXPDARWKPPY-UHFFFAOYSA-N ДаY
Fizički podaci
Tačka topljenja350 °C (662 °F)

OsobineУреди

Osobina Vrednost
Broj akceptora vodonika 5
Broj donora vodonika 2
Broj rotacionih veza 0
Particioni koeficijent[8] (ALogP) -1,5
Rastvorljivost[9] (logS, log(mol/L)) -0,4
Polarna površina[10] (PSA, Å2) 65,8

ReferenceУреди

  1. ^ Pacher P, Nivorozhkin A, Szabo C: Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58(1):87-114. PMID 16507884
  2. ^ Schlesinger N: Diagnosing and treating gout: a review to aid primary care physicians. Postgrad Med. 2010 Mar;122(2):157-61. PMID 20203467
  3. ^ Suzuki I, Yamauchi T, Onuma M, Nozaki S: Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders? Drugs Today (Barc). 2009 May; 45(5):363-78. PMID 19584965
  4. ^ Terkeltaub R: Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010 Jan;6(1):30-8. PMID 20046204
  5. ^ George J, Struthers AD: Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 2009;5(1):265-72. Epub 2009 Apr 8. PMID 19436671
  6. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. 
  7. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. 
  8. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  9. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
  10. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. 

LiteraturaУреди

Spoljašnje vezeУреди

 Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).